

Dignitana expands agreement with GenesisCare to include United States

Dignitana AB, global leader in scalp cooling innovation, announced today an agreement signed with **GenesisCare** to expand their preferred provider network for DigniCap scalp cooling systems to include GenesisCare locations in the United States. The expansion comes on the heels of an initial agreement covering GenesisCare in Australia that was [announced in December](#). The DigniCap® Scalp Cooling System minimizes hair loss from chemotherapy in patients with solid tumors.

Australian-headquartered GenesisCare specializes in the delivery of oncology treatment and is one of the largest networks of integrated oncology care in the world. The network has over 5,000 doctors across 440 locations globally with centers in Australia, the United Kingdom, Spain and the United States. Kicking off the U.S. implementation, DigniCap Delta installations will begin in Florida this spring.

GenesisCare performed a detailed assessment of DigniCap Delta and was selected Dignitana as the preferred provider based on improved patient outcomes, ease of use for clinical staff, and the use of single patient cooling wraps facilitating COVID-19 protocols.

“The success of the DigniCap clinical evaluation in Australia has been quite impressive and we are eager to make this technology available to a wider audience,” said Alyson Tiedeman, GenesisCare U.S. Regional Leader East Florida. “We are committed to providing best in class care for our patients and our partnership with Dignitana provides significant value to our medical oncology patients.”

“GenesisCare is known for exemplary patient care and we are honored to have them on our growing list of DigniCap providers around the globe,” said William Cronin, Dignitana CEO. “Quality of life is extremely important for cancer patients. As awareness of the efficacy of DigniCap increases, demand for this life-changing treatment is growing as well.”

For More Information Contact

Melissa Bourestom, VP Corporate Communications melissa.bourestom@dignitana.com +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, certifiedadviser@redeye.se. Learn more at www.dignitana.se or www.dignicap.com.

About GenesisCare

Sydney-headquartered GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. We're committed to leading the change in how care is given and are currently leading or participating in more than 150 clinical trials. The organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and now the U.S. This follows our acquisition of major U.S. integrated oncology provider 21st Century Oncology in May 2020. Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. For cancer treatment, that includes more than 290 locations in the U.S., 38 locations in Australia, 14 in the UK and 21 in Spain, with more than 30 new centres under development. We also offer cardiology and sleep services at more than 80 locations across Australia. Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our world-class patient satisfaction ratings. For more information visit www.genescare.com.